Nurse Practitioner, Family · New Orleans, LA
NPI
1619320520
Since 2016
Specialty
Nurse Practitioner, Family
Code 363LF0000X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
1514 Jefferson Hwy
New Orleans, LA, 70121
Phone (504) 842-4023
Groups this clinician bills Medicare through
Medicare paid, 2024
$9,768
223 services
Medicare patients, 2024
75
Average age 70
Drug cost, 2024
$3.7M
7,037 prescriptions
Company payments, 2025
$748
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Laura M Matrana was code 99214 (office e&m - established), 117 times for 60 patients. In total Laura M Matrana billed 223 services in 7 codes, and Medicare paid $9,768.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-08-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 117 | 60 | $56.13 | $6,567 |
| 95251 Test - Miscellaneous | Office | 84 | 41 | $20.81 | $1,748 |
By year: 2022 $7,900 for 175 services; 2023 $7,876 for 175 services; 2024 $9,768 for 223 services.
Medicare prescription drug claims, 2024
In 2024, the drug Laura M Matrana prescribed most often to Medicare patients was Ozempic (Semaglutide), with 588 prescriptions and refills. In total Laura M Matrana wrote 7,037 Medicare prescriptions that cost $3.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 588 | 708 | 99 | $667K |
| Mounjaro Tirzepatide | 587 | 658 | 103 | $701K |
| Jardiance Empagliflozin | 506 | 840 | 110 | $485K |
| Farxiga Dapagliflozin Propanediol | 278 | 450 | 55 | $251K |
| Metformin Hcl Generic | 266 | 751 | 83 | $1,464 |
| Atorvastatin Calcium Generic | 240 | 598 | 75 | $2,233 |
| Metformin Hcl Er Metformin Hcl | 236 | 632 | 72 | $1,790 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 229 | 417 | 99 | $20K |
| Rosuvastatin Calcium Generic | 217 | 523 | 66 | $1,795 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 | 174 | 220 | 26 | $152K |
| Tresiba Flextouch U-100 Insulin Degludec | 163 | 205 | 41 | $73K |
| Levothyroxine Sodium Generic | 146 | 273 | 25 | $1,205 |
| Losartan Potassium Generic | 130 | 329 | 39 | $870 |
| Soliqua 100-33 Insulin Glargine/Lixisenatide | 128 | 170 | 35 | $122K |
| Omnipod Dash Pods (Gen 4) Insulin Pump Cart,cont Inf,bt | 118 | 152 | 21 | $120K |
Brand drugs: 3,946 claims; generic drugs: 2,062 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Laura M Matrana $748 ($748 in general payments such as food, travel and fees) from 10 companies. The largest payer was Dexcom, Inc. with $241.
| Company | Payments | Amount |
|---|---|---|
| Dexcom, Inc. DXCM | 5 | $241 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 7 | $155 |
| Insulet Corporation PODD | 5 | $127 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 4 | $96.24 |
| Exact Sciences Corporation EXAS | 2 | $28.7 |
| Novo Nordisk Inc NVO | 1 | $23 |
| Beta Bionics, Inc. BBNX | 1 | $22.87 |
| Sanofi-Aventis U.S. LLC SNY | 1 | $20.77 |
| Sequel Med Tech, LLC | 1 | $17.85 |
| Lilly USA, LLC LLY | 1 | $15.98 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.